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Abstract
Background: Non-small cell lung cancer (NSCLC) is the most frequent cause of cancer deaths worldwide. The
targeted therapy had made important progress in recent years, but few potential predictive biomarkers for
prognosis of NSCLC patients were identified. Angiopoietin-2 (Ang-2), a cytokine upregulated in tumor endothelial
cells and some tumor cells including NSCLC, is a partial agonist and antagonist of angiopoietin-1 (Ang-1). Ang-1
is another ligand for the tyrosine kinase receptor Tie2; it promotes recruitment of pericytes and smooth muscle
cells, stabilizing vascular networks by binding to Tie2. Although many studies mainly considered that Ang-2
correlated with progression and prognosis of NSCLC significantly, there are much conflicting and controversial
data. Therefore, we conducted a meta-analysis to assess the relationship between Ang-2 and prognosis, a clinical
outcome of NSCLC.
Methods: The search was based on major databases from PubMed, Cochrane Library, EMBASE, and CNKI, and
20 eligible publications (range from 2002 to 2015) are included in our meta-analysis with 2011 NSCLC patients
in total. These studies illuminated the correlation between the expression of Ang-2 and NSCLC, based on either
prognostic factors or clinicopathological features. Pooled calculations were carried out on the odds ratio (OR)
and the corresponding 95 % confidence interval (CI) to perform this meta-analysis, and all statistical analyses
were carried out by STATA 12.0 and Review Manager 5.3.
Results: According to our results, the expression of Ang-2 in NSCLC tissues was significantly higher than that
in normal lung tissues, indicating that Ang-2 over-expression may be a predictive marker (pooled OR = 5.09,
corresponding 95 % confidence interval (95 % CI) 3.10–8.36, p = 0.000). In addition, our pooled data showed that
Ang-2 expression was positively correlated with tumor stages (pooled OR = 3.58, 95 % CI 2.40–5.35, p = 0.000),
differentiation (pooled OR = 0.65, 95 % CI 0.45–0.94, p = 0.02), lymphatic invasion (pooled OR = 3.15, 95 % CI 1.97–5.03,
p = 0.000), and poor survival (pooled OR = 1.93, 95 % CI 1.47–2.52, p = 0.000) of NSCLC, but seems to have no
significant impact on tumor size (pooled OR = 1.09, 95 % CI 0.59–2.00, p = 0.78).
Conclusions: These results demonstrate that Ang-2 expression significantly correlated with poor prognosis for
patients with NSCLC.
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Background
Lung cancer is the leading cause of cancer deaths world-
wide, whose 5-year survival rate is only 16 % [1]. In
China, nearly 560,000 people die because of lung cancer;
unfortunately, the incidence and mortality of lung cancer
is still on the rise, especially non-small cell lung cancer
(NSCLC), which makes up 80 % of lung cancer [2]. Due
to the emergence of inhibitors of epidermal growth factor
receptors (EGFRs), anaplastic lymphoma kinase (ALK) and
other targeted drugs, the survival of patients improved
greatly [3–5]. Although the targeted therapy of NSCLC
makes important progress, efforts to identify new add-
itional prognostic and predictive biomarkers for NSCLC
may help to stratify cancer patients, monitor tumor pro-
gression as well as response to the therapy.
Recent evidence suggests that angiogenesis is an estab-
lished hallmark of many solid tumors, while inhibiting
proangiogenic factors demonstrates a potential avenue
for the treatment [6]. Notably, several studies have proved
that angiogenesis results from an imbalance between an-
giogenic and antiangiogenic factors. Vascular endothelial
growth factor (VEGF), as the best known angiogenic
factor, promotes proliferation and migration of endothelial
cell [7, 8]. In addition, it is also known that angiopoietin-2
(Ang-2), a cytokine upregulated in tumor endothelial cells
and some tumor cells including NSCLC, stimulates tumor
angiogenesis in collaboration with VEGF and other
proangiogenic factors [9].
Angiopoietin-1 (Ang-1) and Ang-2 are ligands for the
tyrosine kinase receptor Tie2; they are not only widely
expressed on many embryonic tissues, but also expressed
on some cancer cells. There is a complicated and homeo-
static balance between Ang-1 and Ang-2; some studies
suggest that Ang-2, a partial agonist and inhibitor of
Ang-1, normally restrains Ang-1-induced activation of
the Tie2 receptor [10]. However, other scholars believed
that Ang-2 delivers proangiogenic activity through binding
the Tie2 receptor with the presence of VEGF [11, 12]. Ac-
cumulated evidence shows that the Tie2-signaling path-
way is involved in NSCLC and is a potential therapeutic
target [13]. For example, AMG 386, neutralizing the
interaction between angiopoietins (Ang-1/2) and their
Tie2 receptors, inhibits tumor angiogenesis and tumor
growth successfully [14, 15].
While the role of Ang-2 in angiogenesis and tumor
therapy is well-established, it is also found that Ang-2 ex-
pression is associated with prognosis of various tumors,
such as chronic lymphocytic leukemia [16], hepatocellular
carcinoma [17], colorectal cancer [18], and melanoma
[19]. For example, Volkova et al. analyzed Ang-2 of serum
samples in colorectal cancer patients (n = 344) and con-
firmed serum Ang-2 as a significant predictor for outcome
of colorectal cancer, as well as metastatic CRC treated
with bevacizumab-containing therapy [18].
According to available data, previous studies mainly
considered that Ang-2 correlated with progression and
prognosis of NSCLC significantly. For instance, Coelho
et al. [20] detected circulating Ang-2 messenger RNA
(mRNA) in NSCLC patients’ blood samples (n = 92) and
found that a highly circulating Ang-2 mRNA level serving
as a significantly unfavorable prognostic factor in NSCLC
overall survival is a unique and practical diagnostic tool
to determine prognosis in NSCLC. Furthermore, Fawzy
et al. [21] suggested that serum angiopoietin-2 is a use-
ful marker for the diagnosis of NSCLC by ELISA tech-
nique. Additionally, another study involving 335 unselected
stage I-IIIA NSCLC patients described the relationship
between the Ang-2 expression and survival; illuminated
Ang-4 and Ang-2 were independently associated with
survival, and the expression of VEGF was strongly asso-
ciated with that of Ang-2 [22].
In view of the previous studies, they emphasize that
Ang-2 is significantly relevant to the clinical outcome of
NSCLC [23, 24]. However, Kabalak et al. [25] used the
ELISA method to measure serum VEGF and Ang-2 levels
collected from 100 lung cancer patients (87 NSCLC) and
then found that VEGF and Ang-2 showed a weak positive
correlation; in addition, a higher Ang-2 level in patients
may be useful for differential diagnosis, whereas there was
no relation between Ang-2 levels and survival days signifi-
cantly. Reinmuth et al. [26] analyzed tissue samples of 72
patients with primary stages I and II NSCLC and found
that neither the expression of Ang-2 nor VEGF was asso-
ciated with survival.
Although Ang-2 is implicated in prognosis and clinical
outcome of NSCLC, other studies did report conflicting
results that Ang-2 had no effect on survival. Therefore,
it remains unknown whether this discrepancy is caused by
limited sample sizes, tumor differentiation, tumor stage,
and lymphatic invasion. In this study, a meta-analysis was
performed to assess the relationship between Ang-2
expression and prognosis, a clinical outcome of NSCLC.
Methods
Search strategy
This meta-analysis was carried out in accordance with
the guidelines of the meta-analysis of PRISMA (preferred
reporting items for systematic reviews and meta-analyses).
In this study, we took a comprehensive search strategy
(“angiopoietin-2 OR ANGPT2 protein” and “Carcinoma,
Non Small Cell Lung OR Lung Carcinoma, Non-Small-
Cell OR Non small Cell Lung Cancer”) through an elec-
tronic search on PubMed, Cochrane Library, EMBASE,
and CNKI. We also performed a manual search for the
articles in the references. Articles, incepted and ended on
November 2015, were identified by two investigators
(Xuan ZX and Zhang S) independently. Studies included
in the meta-analysis had to meet the following criteria:
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(1) all patients were pathologically diagnosed as NSCLC
in clinic; (2) the content of Ang-2 was detected in all
patients; and (3) the relationship between the Ang-2
expression and the prognosis of NSCLC patients was
investigated. Articles were excluded based on any of the
following criteria: (1) duplicated articles or data; (2) no
clinical specimens; and (3) abstracts, unpublished studies,
reviews.
Data extraction
Data was extracted independently by two investigators
(Xuan ZX and Zhang S), using a standard form. Any
discrepancies were solved via discussion, and all the
data were subject to consensus. We extracted informa-
tion including first author’s name, year of publication,
country of the study population, case of the study popula-
tion, type of tumor, stage, analysis method, evaluation
method, the follow-up time (months), outcome indexes,
and hazard ratio (HR) (95 % CI). Some studies provided
HR and p; we used the following mathematical for-
mula: b = ln(HR), std = b/inverse_normal_distribution(p/2),
95 % CI = exp(b ± 1.96*std) to calculate the 95 % CI.
Qualitative assessment
Quality assessment of each available study was performed
using the Newcastle–Ottawa Quality Assessment Scale
(NOS) for the Cochrane Non-Randomized Studies. In-
cluded studies were scored for both bias and NOS inde-
pendently by two authors (Xuan ZX and Zhang S), and
referral to the panel made failing consensus agreement,
and a score of 0–9 could be determined to indicate the
quality of each study (Table 1). Studies labeled with five or
more stars were considered to be of high quality.
Statistical analysis
The differences in the studies were shown by the odds
ratio (OR) and the corresponding 95 % confidence inter-
val (CI), and no overlap of the 95 % CI with 1 indicated
a statistical significance. In order to quantify the aggre-
gation of survival results, HR and their 95 % CI were com-
bined to give the effective value, and HR was calculated
from data, which were reported directly or presented in
the form of Kaplan–Meier survival curve. In our study,
the heterogeneity of included studies was tested by the I2
statistic based on Cochran’s Q test, I2 < 50 % or p > 0.1 was
considered to be of low heterogeneity, and the fixed-effect
model was used to calculated the pooled OR; otherwise, a
random-effect model was used because of the significant
heterogeneity. We also evaluated the stability of the results
through removing each study at a time. Two-sided p <
0.05 was considered statistically significant. All statistical
Table 1 Baseline characteristics of the 20 trials used in the meta-analysis
Author Year Country No. of patients Stage Assay Follow-up (months) NOS score
Andersen [20] 2011 Norway 335 I–III IHC 86 8
Coelho [22] 2014 Portugal 92 I–IV RT-PCR NA 6
Daly [27] 2014 USA 197 NA ELISA 60 7
Huang [28] 2012 China 59 I–III IHC NA 6
Jiang [29] 2015 China 50 I–III IHC NA 5
Li [30] 2015 China 88 I–IV ELISA NA 5
Liu [31] 2010 China 50 I–IV IHC 60 7
Liu [32] 2014 China 40 I–IV ELISA 30 6
Massabeau [33] 2008 France 78 III IHC NA 5
Park [34] 2007 South Korea 110 I–IV ELISA 22.1 8
Park [35] 2009 South Korea 101 I–II ELISA NA 5
Sasaki [36] 2012 Japan 110 I–IV RT-PCR 60 8
Takanami [37] 2004 Japan 77 I–III RT-PCR、IHC 60 7
Tanaka [38] 2002 Japan 236 I–III IHC 60 8
Wan [39] 2008 China 98 I–IV ELISA 12 5
Wang [40] 2015 China 114 I–IV IHC NA 7
Xiao [41] 2010 China 41 I–III IHC NA 7
Xing [42] 2003 China 52 I–III RT-PCR NA 7
Yuan [43] 2007 China 46 NA IHC NA 5
Zhang [44] 2008 China 37 I–III IHC NA 7
NA not available, NOS Newcastle–Ottawa Scale, RT-PCR real-time polymerase chain reaction, IHC immunohistochemistry, ELISA enzyme-linked immunosorbent assay
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The flowchart of the study selection process is presented
in Fig. 1. Eleven articles are excluded for no comparative
data based on the difference of Ang-2 expression, or no
assessment of relationship between the Ang-2 expression
and the prognosis of NSCLC. Twenty eligible publications
are included in our meta-analysis with 2011 NSCLC pa-
tients in total [20, 22, 27–44]. These eligible articles were
published from 2002 to 2015. The features of the eligible
studies are shown in Table 1. These studies mainly illumi-
nated the correlation between the expression of Ang-2
and NSCLC, based on either prognostic factors or clinico-
pathological features. One of the 20 studies was from the
USA, 11 studies were from China, three studies were from
Japan, one study was from France, one study was from
Norway, two studies were from South Korea, and one
study was from Portugal. Of them, the NOS score is from
5 to 8, so all of the articles were regarded as high quality.
Different expression of Ang-2 between NSCLC tissues and
normal tissues
For the meta-analysis of two-category variables, there
were six articles, which assessed the correlation between
Ang-2 expression and NSCLC [28, 31, 41–44], our
results demonstrated that Ang-2 expressions in NSCLC
tissues were significantly higher than normal lung tissues
(pooled OR = 5.09, 95 % CI: 3.10–8.36, p = 0.000 and
I2 = 0 %; Fig. 2a). In addition, five articles detected
Ang-2 through ELISA in NSCLC serum or normal serum,
to analyze the relationship between Ang-2 expression and
NSCLC [30, 32, 34, 35, 39]. Due to the high heterogeneity
among these studies (P = 0.000, I2 = 81 %), we chose the
random-effect model. As showed in the Fig. 2b, all the
content of Ang-2 in NSCLC tissues was higher than that
in normal tissues, and Ang-2 over-expression was associ-
ated with NSCLC (control: pooled OR = 0.87, 95 % CI:
0.56-1.18, P = 0.000).
Correlation of Ang-2 expression and clinicopathological
features of NSCLC
There were seven studies investigating the relationship be-
tween Ang-2 expression and tumor stages, TNM stages I
and II were considered as low stage and III and IV as high
stage [28, 29, 31, 38, 40, 41, 44]. Their pooled analysis
revealed that Ang-2 expression significantly associated
with tumor stages (pooled OR = 3.58, 95 % CI: 2.40–5.35,
p = 0.000 and I2 = 0 %; Fig. 3a). Eight studies illuminated
the association of Ang-2 expression with tumor differenti-
ation [28, 29, 31, 38, 40–43]; the combined OR revealed
that there was a significant association between Ang-2
Fig. 1 Flowchart showing study selection procedure
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expression and tumor differentiation (pooled OR = 0.65,
95 % CI: 0.45–0.94, P = 0.02 and I2 = 21 %; Fig. 3b). The
association between Ang-2 expression and lymphatic
invasion is illustrated in Fig. 3c. Ang-2 expression had a
significant relationship with lymphatic invasion in NSCLC
patients [28, 31, 40, 41, 43, 44], with the pooled OR of
3.15 (95 % CI: 1.97–5.03, p = 0.000 and I2 = 26 %). To ex-
plore the relevance between Ang-2 expression and tumor
size, tumors were classified based on the tumor size (cut-
off value was 3 or 5 cm), and three studies were included,
and the combined OR showed that Ang-2 expression was
not significantly associated with tumor size [28, 31, 40],
with a pooled OR estimate of 1.09 (95 % CI: 0.59–2.00,
p = 0.78 and I2 = 0 %; Fig. 3d).
Correlation of Ang-2 expression and survival of NSCLC
patients
The cytoplasmic staining of NSCLC tissues was scored
with regard to density as well: 1 = low, 2 = intermediate,
and 3 = high, and high expression for Ang-2 was defined
as ≥2.5. In our meta-analysis, the NSCLC patients in five
studies were divided into the Ang-2 H (high expression)
group and the Ang-2 L (lower expression) group via the
Ang-2 level, and the overall survival in both groups was
calculated [22, 31, 36–38]. The collected data were signifi-
cantly heterogeneous (p = 0.02, I2 = 65 %). Thus, a random
model was used. This meta-analysis showed that the over-
all survival in Ang-2 L group is tendentiously higher than
that of the Ang-2 H group (pooled OR = 0.65, 95 % CI:
0.34–1.21, p = 0.17; Fig. 4a).
Five studies provided sufficient information about the
correlation of Ang-2 expression and survival of NSCLC
patients, especially the hazard ratio (HR) for overall
survival (OS) or disease-free survival (DFS) and 95 %
confidence interval (CI) [20, 22, 27, 33, 34]. The study
of Daly provided HR = 2.12 and p = 0.094, we used math-
ematical formula to calculate the 95 % CI, that was 0.88–
5.11. Then, pooled data from these five studies suggested
that Ang-2 expression was significantly associated with
poor survival of NSCLC (Fig. 4b). There was no significant
heterogeneity (I2 = 0 %, p = 0.995), and the pooled HR was
1.93 (95 % CI: 1.47–2.52), indicating that Ang-2 expres-
sion predicted worse prognosis in NSCLC.
Sensitivity analysis was carried out to confirm the
stability of the result. As shown in Table 2, the pooled
HRs ranged from 1.90 (95 % CI: 1.40–2.57, p = 0.000) to
1.97 (95 % CI: 1.47–2.63, p = 0.000), and relative hetero-
geneity remained insignificant. Therefore, there was no
individual study that could significantly influence the re-
sult of HR when any individual study was removed from
our meta-analysis.
Discussion
NSCLC is one of common neoplastic diseases, and in-
creasing evidence proves that there is poor prognosis and
limited therapeutic options [45]. Therefore, it is urgent
to identify reliable biomarkers, which may be helpful in
Fig. 2 The difference of the Ang-2 expression on NSCLC patients and control. a For the meta-analysis of two-category variables, six articles assessed
the correlation between Ang-2 expression and NSCLC. b Five articles detected Ang-2 content through ELISA in NSCLC serum or normal serum,
to analyze the relationship between Ang-2 expression and NSCLC
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Fig. 3 Association of Ang-2 expression with clinicopathological parameters. a Seven studies investigated the relationship between Ang-2 expression
and tumor stages, and their pooled results revealed that Ang-2 expression significantly associated with tumor stages. b Eight studies illuminated the
association of Ang-2 expression with tumor differentiation; the combined OR revealed that there was a significant association between Ang-2
expression and tumor differentiation. c Ang-2 expression had a significant relationship with lymphatic invasion in NSCLC patients. d The combined OR
showed that Ang-2 expression was not significantly associated with tumor size
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predicting prognosis and guiding surveillance in NSCLC
[46]. To our knowledge, tumor angiogenesis, characterized
by the formation of new irregular blood vessels derived
from preexisting vascular network, plays a central role
in NSCLC tumor growth. Recently, the angiopoietins
have been shown to be important regulators of neovas-
cularization and endothelial cell survival in malignant
tumors [47]. Considered as the major activating ligand
to the tyrosine kinase receptor Tie2, Ang-1 usually re-
cruits and sustains peri-endothelial supporting cells to
promote endothelial cell survival and vessel stabilization.
In general, Ang-2 has been recognized as a naturally oc-
curring antagonist to Ang-1 and prevents Tie2 activation
[9, 47]. However, some studies have suggested that Ang-2
can either agonize or antagonize the Tie2 receptor, thereby
leading to vascular sprouting or regression [48].
More and more studies indicated that Ang-2 expression
is significantly linked with prognosis of NSCLC [22]. Never-
theless, some studies suggested that Ang-2 levels did not
correlate with survival days, and the association between
Ang-2 and the prognosis of NSCLC remained controversial
[25, 26, 49]. Therefore, we conduct this meta-analysis to
systematically determine the association of Ang-2 levels
with clinicopathological features and prognosis of NSCLC.
Firstly, we assessed the difference of Ang-2 expression
between NSCLC tissues and normal tissues. Our result
revealed that the expression of Ang-2 in NSCLC tissues
was significantly higher than that in normal lung tissues
either through two-category variables or continuous vari-
able analysis, and Ang-2 over-expression may be a predict-
ive marker because of the correlation with NSCLC. Then,
we also studied the pooled association between Ang-2
expression and clinicopathological features. The pooled
data of our results indicated that Ang-2 expression was
positively correlated with TNM stages, tumor differenti-
ation, and lymphatic invasion of NSCLC. These results
of meta-analysis supported the hypothesis that Ang-2
might contribute to malignant progression of NSCLC,
which subsequently leads to a poorer prognosis. Further-
more, the correlation of Ang-2 expression and survival of
NSCLC patients was also assessed; the pooled data indi-
cated that Ang-2 expression significantly predicted poor
survival (Table 3). Moreover, removing one individual
Fig. 4 Association of Ang-2 expression with survival. a NSCLC patients in five studies were divided into Ang-2 H (high expression) group and
Ang-2 L (lower expression) group via the Ang-2 level, and results showed that the overall survival in the Ang-2 L group is tendentiously higher
than that of the Ang-2 H group. b The pooled data from these five studies suggested that Ang-2 expression was significantly associated with
poor survival of NSCLC
Table 2 Sensitivity analysis for different expressions of Ang-2
between NSCLC tissues and normal tissues
Study omitted Resulting HR (95 % CI)
None 0.87 (0.56–1.18)
Li 2005 0.89 (0.52–1.25)
Liu 2014 0.73 (0.50–0.96)
Park 2007 0.90 (0.47–1.32)
Park 2009 0.98 (0.69–1.27)
Wan 2008 0.85 (0.44–1.26)
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study could not significantly change the linear trend and
the stability of the result.
Conclusions
In conclusion, we conducted a systematical and compre-
hensive meta-analysis to assess the relationship between
Ang-2 expression and prognosis, a clinical outcome of
NSCLC, and the prognostic significance of Ang-2 expres-
sion for NSCLC was identified by comparing the depth of
tumor stages, tumor differentiation, lymphatic invasion,
and other clinicopathological features. Eventually, our data
showed that Ang-2 expression is significantly linked with
poor prognosis for patients with NSCLC.
However, it was shown that Ang-2 expression did not
significantly link with tumor size, but there were only
three studies included, and tumors divided into two por-
tions based on tumor size were 3 or 5 cm, so the research
about relationship between tumor size and Ang-2 expres-
sion should be studied in the future. Additionally, current
data about Ang-2 expression and NSCLC prognosis is
limited, and some studies containing negative conclusions
were not published. Only large studies illuminating the
prognostic value of Ang-2 in NSCLC substantiated our
conclusions; Ang-2 expression may act as a potential pre-
dictor for prognosis of patients with NSCLC. Ang-2 will
provide useful information for a therapeutic target to treat
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